{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:04Z","timestamp":1791262444410,"version":"4.1.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In Eastern and Southern Africa, 63% of new HIV infections occurred in women and girls, with adolescent girls and young women representing a particularly vulnerable subpopulation. Effective vaginal products for HIV prevention are desirable because they are underrepresented in the currently approved portfolio and have attributes motivating product use. In this trial, we evaluated an innovative intravaginal ring (pod-IVR) as a platform for HIV pre-exposure prophylaxis (PrEP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To measure the safety and multicompartment pharmacokinetics (PKs) of a pod-IVR delivering tenofovir disoproxil fumarate (TDF) combined with emtricitabine (FTC) in healthy women over 28 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Phase 1 clinical trial consisted of a randomized order, controlled, double-blinded, crossover design. Ten women received either an active TDF-FTC pod-IVR or a placebo pod-IVR for 28 days, determined by 1:1 randomization, followed by product crossover for another 28 days. Safety was assessed in terms of adverse events related to product use, colposcopic examination, cervicovaginal epithelium thickness measurement by optical coherence tomography, and culture-independent assessment of the vaginal microbiome. Drug and\/or drug metabolite concentrations were measured in cervicovaginal fluid (CVF), vaginal tissue, rectal tissue, rectal fluid, and plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no evidence of a statistically significant difference in related adverse-event counts between study products. There also was no evidence suggesting the study product altered the vaginal microbiome systematically or reproducibly. Systemic plasma exposure to tenofovir (TFV) and FTC was low, consistent with topical delivery. High median CVF concentrations of TFV (38.9 ng mg\n                      <jats:sup>-1<\/jats:sup>\n                      ; 135\u00d710\n                      <jats:sup>3<\/jats:sup>\n                      fmol mg\n                      <jats:sup>-1<\/jats:sup>\n                      ) and FTC (239 ng mg\n                      <jats:sup>-1<\/jats:sup>\n                      ; 966\u00d710\n                      <jats:sup>3<\/jats:sup>\n                      fmol mg\n                      <jats:sup>-1<\/jats:sup>\n                      ) were measured. Median vaginal tissue concentrations of the anabolites responsible for inhibition of HIV reverse transcriptase exceeded our target concentrations: TFV diphosphate 0.651\u00d710\n                      <jats:sup>3<\/jats:sup>\n                      fmol mg\n                      <jats:sup>-1<\/jats:sup>\n                      and FTC triphosphate 0.180\u00d710\n                      <jats:sup>3<\/jats:sup>\n                      fmol mg\n                      <jats:sup>-1<\/jats:sup>\n                      . Drug concentrations in rectal tissue samples generally were below the analytical lower limits of quantification, but were quantifiable in rectal fluids, 130 (TFV) and 300 (FTC) times lower than in CVF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TDF-FTC pod-IVRs were safe and well-tolerated over the 28 days of consecutive use. The PK data met the target benchmarks associated with protection from vaginal HIV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT03255915<\/jats:ext-link>\n                      , identifier NCT03255915.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1955105","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:57Z","timestamp":1791260757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An intravaginal ring for HIV pre-exposure prophylaxis: assessment of safety and pharmacokinetics in a randomized, placebo-controlled clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Kathleen L.","family":"Vincent","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Medical Branch","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]},{"name":"Department of Pathology, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pyles","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Medical Branch","place":["Galveston, TX, United States"]},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Medical Branch","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevelyn J.","family":"Olive","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Medical Branch","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Butkyavichene","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia E.","family":"Castonguay","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John M.","family":"Cortez","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Remedios-Chan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galvan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy P.","family":"Adler","sequence":"additional","affiliation":[{"name":"Jumpstart Research Consulting, LLC","place":["Santa Fe, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles (UCLA)","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M. L.","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Kelly Government Solutions, Contractor to Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Rockville, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]},{"name":"Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Anton","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science","place":["Monrovia, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/nejmoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijpharm.2015.09.028","article-title":"An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate","volume":"495","author":"Baum","year":"2015","journal-title":"Int. J. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An intravaginal ring for the simultaneous delivery of multiple drugs","volume":"101","author":"Baum","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0924-977x(03)00109-3","article-title":"A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia","volume":"14","author":"Bhanji","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jchromb.2016.02.033","article-title":"Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples","volume":"1017","author":"Churchman","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"B7","unstructured":"Addendum 1, female genital grading table for use in microbicide studies\n          \n          \n          Rockville, MD\n          Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services\n          Addendum 1, Female Genital Grading Table for Use in Microbicide Studies\n          \n          2017"},{"key":"B8","unstructured":"Addendum 3 rectal grading table for use in microbicide studies (clarification dated May 2012)\n          \n          \n          Rockville, MD\n          Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services\n          Addendum 3 Rectal Grading Table for Use in Microbicide Studies (Clarification Dated may 2012)\n          \n          2017"},{"key":"B9","article-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events","volume-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26457","article-title":"PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub-Saharan Africa","volume":"28","author":"Fonner","year":"2025","journal-title":"J. Int. AIDS Soc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/qai.0000000000003756","article-title":"Higher acceptability of the monthly dapivirine ring versus daily oral pre-exposure prophylaxis among adolescent girls and young women in sub-Saharan Africa in the REACH trial","volume":"100","author":"Friedland","year":"2025","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184303","article-title":"Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice","volume":"12","author":"Gallay","year":"2017","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1002\/jps.24154","article-title":"An intravaginal ring for the sustained delivery of antibodies","volume":"103","author":"Gunawardana","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/aac.02542-13","article-title":"Sustained delivery of commensal bacteria from pod-intravaginal rings","volume":"58","author":"Gunawardana","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197269","article-title":"User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences","volume":"13","author":"Guthrie","year":"2018","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00019053-200523001-00002","article-title":"Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models","volume":"23","author":"Haycox","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)","volume":"32","author":"Hendrix","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments","volume":"8","author":"Hendrix","year":"2013","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/s0140-6736(11)60878-7","article-title":"Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women","volume":"378","author":"Karim","year":"2011","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/qai.0000000000000607","article-title":"Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: Importance of adherence for microbicide effectiveness","volume":"69","author":"Kashuba","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/978-3-540-38918-7_115","article-title":"Safety and pharmacokinetics of acyclovir in women following release from a silicone elastomer vaginal ring","volume":"67","author":"Keller","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E498","DOI":"10.1016\/s2352-3018(19)30145-6","article-title":"Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial","volume":"6","author":"Keller","year":"2019","journal-title":"Lancet HIV"},{"key":"B23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.aai9383","article-title":"Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women","volume":"356","author":"Klatt","year":"2017","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/bf00314990","article-title":"Dosage frequency and drug compliance behavior - a comparative study on compliance with a medication to be taken twice or 4 times daily","volume":"41","author":"Kruse","year":"1991","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/1568005033481079","article-title":"Is resistance futile","volume":"3","author":"Kutilek","year":"2003","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2307\/2530604","article-title":"Analysis of Poisson data in crossover experimental designs","volume":"34","author":"Layard","year":"1978","journal-title":"Biometrics"},{"key":"B27","first-page":"221","article-title":"Microbicide vaginal rings","volume-title":"Drug Delivery and Development of Anti-HIV Microbicides","author":"Moss","year":"2014"},{"key":"B28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/qad.0b013e3283509abb","article-title":"Tenofovir and tenofovir disoproxil pharmacokinetics from intravaginal rings","volume":"26","author":"Moss","year":"2012","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1128\/aac.00391-16","article-title":"Combination pod-intravaginal ring delivers antiretroviral agents for HIV prophylaxis: Pharmacokinetic evaluation in an ovine model","volume":"60","author":"Moss","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18070829","article-title":"Preclinical pharmacokinetics of a triple-combination intravaginal ring for HIV prevention","volume":"18","author":"Moss","year":"2026","journal-title":"Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1128\/aac.02871-14","article-title":"Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model","volume":"58","author":"Moss","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1016\/s2352-3018(23)00227-8","article-title":"Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: A randomised, open-label, crossover trial","volume":"10","author":"Nair","year":"2023","journal-title":"Lancet HIV"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/nejmoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/s2352-3018(20)30300-3","article-title":"Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study","volume":"8","author":"Nel","year":"2021","journal-title":"Lancet HIV"},{"key":"B35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation","volume":"29","author":"Nugent","year":"1991","journal-title":"J. Clin. Microbiol."},{"key":"B36","unstructured":"The dapivirine vaginal ring\n          \n          \n          AVAC New York\n          The Dapivirine Vaginal Ring\n          \n          2026"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093419","article-title":"Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures","volume":"9","author":"Pyles","year":"2014","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001361","article-title":"Depot haloperidol decanoate for schizophrenia","volume":"2","author":"Quraishi","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","article-title":"Vaginal rng acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world","volume":"106","author":"Ridgeway","year":"2022","journal-title":"Contraception"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032728","article-title":"Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures","volume":"7","author":"Rose","year":"2012","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26498","article-title":"Seizing the moment: The potential of PrEP choice and innovation to transform HIV prevention","volume":"28","author":"Schmidt","year":"2025","journal-title":"J. Int. AIDS Soc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/s0169-409x(02)00090-x","article-title":"Implantable, polymeric systems for modulated drug delivery","volume":"54","author":"Sershen","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IJWH.S185712","article-title":"We are not the same\": African women's view of multipurpose prevention products in the TRIO clinical study","volume":"11","author":"Shapley-Quinn","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907x233403","article-title":"A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch","volume":"23","author":"Small","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges","volume":"110","author":"Smith","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157061","article-title":"Topical delivery of tenofovir disoproxil fumarate and emtricitabine from pod-intravaginal rings protect macaques from multiple SHIV exposures","volume":"11","author":"Srinivasan","year":"2016","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99545","article-title":"Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics","volume":"3","author":"Taneva","year":"2018","journal-title":"JCI Insight"},{"key":"B48","unstructured":"Fact sheet 2025 - global HIV satistics\n          \n          \n          UNAIDS Geneva\n          Fact Sheet 2025 - Global Hiv Satistics\n          \n          2025"},{"key":"B49","unstructured":"Fact sheet 2026 - global HIV satistics\n          \n          \n          UNAIDS Geneva\n          Fact Sheet 2026 - Global Hiv Satistics\n          \n          2026"},{"key":"B50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.antiviral.2013.12.004","article-title":"Comparison of the vaginal microbial communities in HSV-2 seropositive women receiving medicated intravaginal rings","volume":"102","author":"Ursell","year":"2014","journal-title":"Antiviral Res."},{"key":"B51","volume-title":"Guidance for Industry: Bioanalytical Method Validation","year":"2001"},{"key":"B52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/apc.2017.0075","article-title":"Favoring \u201cpeace of mind\u201d: A qualitative study of African women's HIV prevention product formulation preferences from the MTN-020\/ASPIRE trial","volume":"31","author":"Van Der Straten","year":"2017","journal-title":"AIDS Patient Care STDS"},{"key":"B53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/olq.0b013e31815abad8","article-title":"Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: Potential for assessment of microbicide safety","volume":"35","author":"Vincent","year":"2008","journal-title":"Sex Transm. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/olq.0b013e31819496e4","article-title":"High resolution imaging of epithelial injury in the sheep cervicovaginal tract: A promising model for testing safety of candidate microbicides","volume":"36","author":"Vincent","year":"2009","journal-title":"Sex Transm. Dis."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201952","article-title":"Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention.: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc","volume":"13","author":"Vincent","year":"2018","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002655","article-title":"Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A phase I trial","volume":"15","author":"Vincent","year":"2018","journal-title":"PloS Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/aog.0b013e318238f563","article-title":"Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage a randomized controlled trial","volume":"118","author":"Vincent","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.01.025","article-title":"Monitoring vaginal epithelial thickness changes noninvasively in sheep using optical coherence tomography","volume":"208","author":"Vincent","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J. Manage. Care Pharm."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02465-16","article-title":"Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1955105\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:00Z","timestamp":1791260760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1955105\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":60,"alternative-id":["10.3389\/fcimb.2026.1955105"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1955105","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1955105"}}